MGTX MeiraGTx Holdings Company Cash Funds

MGTX (meiragtx.com) - company brandmark

Geopolitical instability and the disruption of biomaterial logistics are hindering the global research efforts of MeiraGTx Holdings plc (MGTX), rendering the current status equal to 0.18. The company's remaining cash on hand clearly demonstrates liquidity resilience against macroeconomic shocks. Revenue growth is driven by the sale of therapies for hereditary vision pathologies, while unique vector production capacities create an insurmountable barrier to entry for new players.

MGTX - MeiraGTx PLC Company Cash Position over the range 07/04/2022 - 11/21/2026

Financial and market metric breakdowns for MeiraGTx Holdings (MGTX)

- stock quotes and analyst forecast:
Fundamental company valuation:MGTX MeiraGTx Holdings plc
Product sample of MeiraGTx

This indicator measures the total volume of liquid assets, determining the business's ability to cover operating expenses and liabilities without seeking external financing. By analyzing the cash asset volume, investors assess the autonomy of MeiraGTx Holdings plc (MGTX), for which a capital reserve is critically important during gene therapy development, as the cost of borrowed funds directly impacts the stability of this non-cyclical business.

Competing companies

Company Cash Volume TEM|QGEN - Company Cash Reserve|ionispharma.com - Company Cash on Hand|Company Cash Balance RGEN|Avidity Corp - Company Cash Volume|CRISPR Therapeutics Corp - Company Total Cash Amount|GeneDx Holdings (WGS) - Company Cash Funds|Ultragenyx Pharmaceutical (RARE) - Company Cash Volume|Company Cash on Hand BEAM|Sarepta (SRPT) - Company Liquid Assets|Company Cash Funds Twist Bioscience Corp (TWST)|10x - Company Cash and Cash Equivalents|Company Cash Volume NTLA (intelliatx.com)|Company Total Cash Amount STOK (stoketherapeutics.com)|BioLife Solutions Inc - Company Cash Volume|WVE (Wave Life Sciences Ltd) - Company Cash and Cash Equivalents|Maze Therapeutics Corp (MAZE) - Company Cash Funds|Company Cash and Cash Equivalents SION|PRME (Prime Medicine Inc) - Company Cash Volume|Taysha Gene Therapies (TSHA) - Company Liquid Assets|Company Cash on Hand QURE (uniqure.com)|REGENXBIO (RGNX) - Company Cash Position|Company Cash Volume SLDB (Solid Biosciences Inc.)|Company Cash Balance OCGN|PacBio Corp - Company Cash Volume|Benitec Biopharma Inc. (BNTC) - Company Cash on Hand|DSGN: Company Cash Volume|Company Cash and Cash Equivalents RCKT|Company Cash on Hand FDMT|Company Cash and Cash Equivalents LXEO (Lexeo Therapeutics)|Company Cash Volume KRRO|Editas Medicine, Inc. - Company Cash and Cash Equivalents|Company Cash Funds Silence Therapeutics Inc. SLN|Company Cash Volume ProQR Therapeutics N.V. PRQR|CDXS: Company Cash on Hand|Company Cash Position Sangamo (SGMO)|NAUT (Nautilus Bio) - Company Cash on Hand|MGX - Company Liquid Assets|DTIL (Precision BioSciences Inc.) - Company Cash Volume|generationbio.com (GBIO) - Company Liquid Assets|Company Cash Funds Boundless Bio Inc (BOLD)|Company Cash Volume Exicure Inc. (XCUR)|Company Cash Funds imunon.com IMNN|Company Cash Volume Phio Pharmaceuticals PHIO|Mustang Bio Inc - Company Cash Volume|Company Cash Reserve transcodetherapeutics.com|BNGO: Company Cash Volume|Company Cash and Cash Equivalents APDN|BLUE (bluebirdbio.com) - Company Cash Volume|Company Cash Reserve ImmunoPrecise Antibodies IPA|Company Cash on Hand OMGA (omegatherapeutics.com)|Company Cash Volume Singular Genomics Systems, Inc. (OMIC)|Company Cash Volume RGLS (Regulus Therapeutics, Inc.)|Company Cash Volume Syros SYRS|Telesis Bio, Inc. - Company Cash Volume|TRACON Pharmaceuticals (TCON) - Company Cash on Hand|UBX: Company Cash Volume